KOL Insight Archives | Report Store

Ovarian Cancer Pulse Survey

$599.00

Diagnostics/diagnostic techniques discussed:

etarfolatide/folic acid, BRCA mutation testing

May 7, 2014

Find out more

Biomedtracker Q3 2017 Outlook Report

$599.00

In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

August 2, 2017

Find out more

Datamonitor Healthcare Systemic Lupus Erythematosus KOL Interviews

$599.00

Datamonitor Healthcare interviewed two experts on systemic lupus erythematosus (SLE) based in the US to gauge their views on currently available treatment options, pipeline drugs and challenges with clinical trial design in SLE.

August 18, 2017

Find out more

Dyslipidemia and Diabetes Reimbursement KOL Interview:

$599.00

Topics: Dyslipidemia and Diabetes Reimbursement PCSK9 Inhibitors, SGLT2/DPP4 Inhibitor FDCs, and Biosimilar Insulin

August 5, 2015

Find out more

2015 Breast Cancer Pulse #2

$599.00

This 5-question pulse of 24 oncologists practicing in the United States focuses on the usage of HER2-targeted agents for the treatment of breast cancer.

May 26, 2015

Find out more

Pulmonary Hypertension KOL Interview – Germany

$599.00

This interview with a Germany-based key opinion leader (KOL) provides insights into current prescribing habits on- and off-label in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Uptravi, Opsumit, Tyvaso, Remodulin (and Remunity), Adcirca, INOpulse, and sotatercept.

July 21, 2022

Find out more

Rheumatoid Arthritis KOL Interview – UK

$599.00

A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

July 31, 2019

Find out more

Ovarian Cancer KOL Interview – UK

$599.00

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for ovarian cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include veliparib, mirvetuximab soravtansine, Recentin, ofranergene obadenovec, dostarlimab, Tecentriq, Keytruda, Imfinzi, and Opdivo.

April 2, 2020

Find out more

Type 1 Diabetes KOL Interview – US, Midwest

$599.00

This interview with a US Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes, as well as pricing pressures within the diabetes market.

January 8, 2020

Find out more

Chronic Lymphocytic Leukemia (CLL) KOL Interview – Italy

$599.00

An Italy-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Key pipeline assets highlighted include non-covalent BTK inhibitors, Brukinsa, and CD19-directed CAR-T therapies.

March 17, 2022

Find out more

Atopic Dermatitis and Psoriasis KOL Interview – US, South

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

November 18, 2021

Find out more

Chronic Neuropathic Pain KOL Survey

$599.00

Biomedtracker performed a 5-question survey of 30 United States neurologists who currently treat patients with chronic neuropathic pain and prescribe opioids to at least some of their patients with chronic neuropathic pain to gauge current use of adjuvants (TCAs, anti-convulsants, SNRIs, SSRIs, and NMDA receptor antagonists) and potential future use of cebranopadol and raxatrigine to treat chronic neuropathic pain.

March 9, 2017

Find out more

Datamonitor-Acute-Myelogenous-Leukemia-KOL-Interview

Acute Myelogenous Leukemia (AML) KOL Interview

$599.00

Datamonitor interviewed three oncology specialists to determine the physicians’ views on marketed and pipeline therapies for Acute Myelogenous Leukemia. Two physicians were based in the US (Greater Midwest and Greater Boston areas) and one in the UK. The three interviews were combined into a single report.

August 19, 2016

Find out more

Chronic Lymphocytic Leukemia (CLL) KOL Interview – US, South #1

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.

March 17, 2022

Find out more

Schizophrenia and Bipolar Disorder KOL Interview – Germany

$599.00

This interview with an EU-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

April 28, 2021

Find out more